DOJ charges former Five Prime trialist with securities fraud after $134K in insider trading profits
The director of the gastrointestinal oncology program at the University of Chicago Medical Center has been charged by the US attorney in Chicago with insider trading after he made more than $134,000 from stock trades based on an early look at the results of a Five Prime Therapeutics trial.
The US attorney’s office said yesterday that back in early November 2020, Daniel Catenacci, a University of Chicago associate professor with more than a decade of experience who worked with Five Prime on early trials, purchased more than 8,700 shares of the company the morning before it announced positive results from a Phase II trial in treating advanced gastric/gastroesophageal cancer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 147,500+ biopharma pros reading Endpoints daily — and it's free.